Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 8/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492753 | 0.93 | TRPV4 (0.36) | TRPV4BDKRB1CNR2OPRM1OPRD1 | |
| SCHEMBL493347 | 0.90 | TDP1 (0.39) | SLC9A3MAPTLMNATP53POLB | |
| SCHEMBL492489 | 0.88 | BDKRB1 (0.37) | TRPV4BDKRB1CNR2SLC9A3GSTO1 | |
| SCHEMBL492842 | 0.85 | BDKRB1 (0.36) | TRPV4BDKRB1CNR2SLC9A3GSTO1 | |
| SCHEMBL493332 | 0.85 | BDKRB1 (0.36) | TRPV4BDKRB1CNR2SLC9A3OPRM1 | |
| SCHEMBL493214 | 0.85 | BDKRB1 (0.43) | BDKRB1MAPTL3MBTL1PKM | |
| SCHEMBL493141 | 0.84 | BDKRB1 (0.36) | BDKRB1OPRM1L3MBTL1ALDH1A1PKM | |
| SCHEMBL493097 | 0.84 | POLB (0.40) | BDKRB1MAPTLMNAPOLBTDP1 | |
| SCHEMBL493462 | 0.84 | TP53 (0.37) | MAPTLMNATP53POLBTDP1 | |
| SCHEMBL492795 | 0.83 | BDKRB1 (0.51) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | TRPV4 217/4885BDKRB1 1622/4885CNR2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.